Anthem Biosciences Q1 Results FY27: Net Profit Falls 11.7% to Rs 119 Crore as Revenue Declines 22.6%

Anthem Biosciences Q1 FY27: consolidated PAT Rs 119 Cr, down 11.7% YoY. Revenue Rs 418 Cr, down 22.6%. Gross profit down 26.9% at Rs 120 Cr. Shares trading down 2.53% as of 22 July 2026.

Anthem Biosciences Q1 results FY27 were announced on Tuesday, 21 July 2026, with the company reporting the numbers summarised below on a consolidated basis for the quarter ended 30 June 2026.

Shares of Anthem Biosciences were trading down 2.93 at Rs 768.35 on the NSE as of Wednesday, 22 July 2026. The contract research, development and manufacturing (CRDMO) company, among the more recent additions to the exchanges, reported a decline across every metric.

Click Here – Get Free Investment Predictions

Anthem Biosciences Q1 Results FY27 Key Takeaways

Here are the most important numbers from the Anthem Biosciences Q1 results FY27 at a glance.

• Revenue: Rs 418 Cr in Q1 FY27 versus Rs 540 Cr in Q1 FY26, down 22.6% year on year.
• Gross Profit: Rs 120 Cr in Q1 FY27 versus Rs 165 Cr in Q1 FY26, down 26.9% year on year.
• Net Profit (PAT): Rs 119 Cr in Q1 FY27 versus Rs 135 Cr in Q1 FY26, down 11.7% year on year.
• Anthem Biosciences shares were trading down 2.93 at Rs 768.35 as of Wednesday, 22 July 2026.

Anthem Biosciences Q1 Results FY27 Financial Highlights

The table below summarises the consolidated numbers reported in the Anthem Biosciences Q1 results FY27 against the year ago quarter.

All figures are on a consolidated basis as reported for the quarter ended 30 June 2026.

Anthem Biosciences Q1 Results FY27 Performance Analysis

Get Personalised Guidance from a SEBI-Registered Investment Advisor

The Anthem Biosciences Q1 results FY27 show a broad based decline, with revenue falling 22.6%, gross profit falling further at 26.9%, and net profit falling a comparatively smaller 11.7%. The fact that PAT fell less than revenue and gross profit suggests some cost flexibility or a favourable item below the operating line cushioned the bottom line.

For a CRDMO business serving pharmaceutical and biotech clients, revenue can be lumpy quarter to quarter depending on the timing of large development and manufacturing contracts. A 22.6% revenue decline in the Anthem Biosciences Q1 results FY27 may reflect the phasing of specific projects rather than a broad demand slowdown, though this needs confirmation from management commentary.

The relatively contained stock reaction of a 2.93% decline, smaller than the scale of the revenue and gross profit falls, suggests the market may already be pricing in some quarter to quarter lumpiness typical of contract research and manufacturing businesses.

Anthem Biosciences Q1 Results FY27: Key Business Factors

1. Revenue Decline Steeper Than Profit Decline

PAT falling 11.7% against a 22.6% revenue decline in the Anthem Biosciences Q1 results FY27 suggests the company retained some cost flexibility or had a favourable item below the operating line.

2. Possible Project Timing Effects

As a CRDMO business, revenue often depends on the phasing of large pharmaceutical development and manufacturing contracts, which can create lumpy quarter to quarter comparisons.

3. Margin Compression at the Gross Level

Gross profit falling 26.9%, faster than revenue, in the Anthem Biosciences Q1 results FY27 indicates some margin pressure within the core operations that investors should track into the next quarter.

Dividend Details

Any dividend announcement accompanying the June 2026 quarter results will be reflected in the company’s official NSE and BSE filings. Investors should rely on those filings for dividend confirmation rather than secondary sources.

Anthem Biosciences Q1 Results FY27 Outlook for the Full Year

After the Anthem Biosciences Q1 results FY27, the key question is whether the revenue decline reflects contract timing that will reverse in coming quarters or a more sustained demand softness. Management commentary on the CRDMO order pipeline and new contract wins will be important signals for FY27.

Anthem Biosciences Stock Performance After the Q1 Results

Download the Univest iOS App or Univest Android App to track Anthem Biosciences live share price and upcoming quarterly results.

Anthem Biosciences shares were trading down 2.93 at Rs 768.35 on the NSE as of Wednesday, 22 July 2026, a day after the Anthem Biosciences Q1 results FY27 were announced.

Investors can compare the trend of the counter with the Nifty 500 index to judge how the stock is placed relative to the broader market after the Anthem Biosciences Q1 results FY27.

Key Risks

Investors going through the fine print of the Anthem Biosciences Q1 results FY27 should also weigh the following risks.

1. Contract and Revenue Lumpiness

CRDMO revenue can swing significantly quarter to quarter based on project timing, making the Anthem Biosciences Q1 results FY27 potentially not fully representative of the underlying demand trend.

2. Client Concentration Risk

Contract research and manufacturing businesses often have revenue concentrated among a smaller number of large pharmaceutical and biotech clients, a structural risk.

3. Recently Listed Stock Volatility

As a relatively recent listing, the stock may see sharper price swings on quarterly results until a longer track record of consistent performance is established.

Conclusion

Anthem Biosciences Q1 results FY27 show net profit down 11.7% at Rs 119 crore on a steeper 22.6% revenue decline, a mixed print for the CRDMO company. Investors should track order pipeline commentary into the September quarter and consult a SEBI-registered advisor before acting on the numbers.

Frequently Asked Questions on Anthem Biosciences Q1 Results FY27

When were the Anthem Biosciences Q1 results FY27 announced?

Ans. The Anthem Biosciences Q1 results FY27 were announced on Tuesday, 21 July 2026, for the quarter ended 30 June 2026, on a consolidated basis.

What is the PAT in the Anthem Biosciences Q1 results FY27?

Ans. The consolidated PAT in the Anthem Biosciences Q1 results FY27 stood at Rs 119 crore, down 11.7% from Rs 135 crore in Q1 FY26.

What was the revenue in the Anthem Biosciences Q1 results FY27?

Ans. Revenue in the Anthem Biosciences Q1 results FY27 stood at Rs 418 crore, down 22.6% from Rs 540 crore in Q1 FY26.

Why did Anthem Biosciences revenue fall in Q1 FY27?

Ans. The Anthem Biosciences Q1 results FY27 show a 22.6% revenue decline, which may reflect the timing of large contract research and manufacturing projects typical of the CRDMO business model rather than a broad demand slowdown, though this needs confirmation from management commentary.

What does Anthem Biosciences do?

Ans. The company is a contract research, development and manufacturing organisation (CRDMO) serving pharmaceutical and biotechnology clients.

How is the stock trading after the Anthem Biosciences Q1 results FY27?

Ans. Anthem Biosciences shares were trading down 2.93% at Rs 768.35 on the NSE as of Wednesday, 22 July 2026, a day after the Anthem Biosciences Q1 results FY27 were announced.

Is the stock a good buy after the Anthem Biosciences Q1 results FY27?

Ans. The Anthem Biosciences Q1 results FY27 show a broad based decline that warrants tracking the order pipeline for signs of a rebound. This article is for educational purposes only. Consult a SEBI-registered advisor before investing.

Where can I verify the Anthem Biosciences Q1 results FY27?

Ans. The official filings for the June 2026 quarter are available on the NSE and BSE websites, and the stock can be tracked on the Univest app.